– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway – Strong cash position with $119 million of cash and cash equivalents as of March 31, 2021 , and cash
NEW YORK and RESEARCH TRIANGLE PARK, N.C , May 19, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present
- GM1 ganglioside in CSF reduced in 4 out of 5 children treated with the lowest dose at 6 months follow-up - Direct evidence of biochemical effect in the CNS suggests intravenous gene therapy may address both the systemic and neurological manifestations of GM1 gangliosidosis - Dr.
NEW YORK , and RESEARCH TRIANGLE PARK, N.C. , April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced four upcoming oral
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene therapy program NEW YORK
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will
- Company had $81 million of cash and cash equivalents as of December 31, 2020 , and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb.
Company expects to receive an additional $4.8 million by mid-2021 upon approval of cenobamate in Europe, totaling over $16.4 million in aggregate net proceeds this year NEW YORK and RESEARCH TRIANGLE PARK, N.C. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.
